Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/19/2015 - 04/20/2018

This course is closed. Please look for other available products in CPNP University.

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Opioid abuse and overdose are serious public health issues within the United States. Pain reliever dependence or abuse rose from 1.5 to 2.1 million between 2002 and 2012, and heroin dependence grew from 214,000 in 2007 to 467,000 in 2012. Drug overdose has been steadily increasing and is now the leading cause of death by injury in the US. In 2010, 75% percent of prescription overdoses involved opioid analgesics. When benzodiazepines are combined with opioids, patients are at even greater risk for morbidity and mortality.

Buprenorphine is the only partial agonist therapy currently approved for managing opioid dependence in an office-based setting. Despite demand, there continues to be a shortage of community treatment options. Buprenorphine’s monitoring demands, unique medication properties, and risk for diversion allow for an important role for pharmacists. Bethany DiPaula, PharmD, BCPP will discuss the supporting evidence and controversies of buprenorphine/naloxone maintenance treatment of opioid use disorders with an emphasis on the psychiatric pharmacist’s role in managing these patients.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Learning Objectives

  1. Evaluate the efficacy and safety of buprenorphine in the treatment of opioid dependence in the outpatient setting.
  2. Examine the consequences of buprenorphine being co-prescribed with benzodiazepines and other potential drugs of abuse.
  3. Construct a response to controversies associated with buprenorphine including the non-medical use of buprenorphine, inpatient continuation, dosing, prescriber qualifications, and patient limits.
  4. Describe the role of the psychiatric pharmacist in buprenorphine outpatient opioid dependence treatment.

Continuing Education Credit and Disclosures

Activity Dates: 06/19/2015 - 04/20/2018
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-15-012-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.10 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-15-012-H01-P (1.0 contact hours).

Grant Support

This activity is partially supported by an educational grant from Sunovion Pharmaceuticals, Inc.